Drug intelligence / Profile preview

metizoline

Development stage: Unknown
Modality: Small Molecules
Administration: Intranasal, Topical (nasal)

Overview

Metizoline is an imidazoline derivative used primarily as a topical nasal decongestant. It acts as a sympathomimetic agent, producing vasoconstriction in the nasal mucosa by stimulating alpha-adrenergic receptors, thereby reducing swelling and congestion. Metizoline is typically formulated as its hydrochloride salt for pharmaceutical use. Its main indication is the relief of nasal congestion associated with conditions such as rhinitis or sinusitis.

Brand names: Ellsyl
Other names: metizoline hydrochloridemetizoline HCl

Targets

ADRA1 (Alpha-1 adrenergic receptor family)

Beyond the preview

Go deeper on metizoline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metizoline.

Explore the full profile